ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
Chronic myeloid leukemia (CML) is a hematological tumor marked by the bcr-abl fusion gene formed by t (9;22) (q34;q11), which translated into the BCR-ABL protein. Tyrosine kinase inhibitors (TKIs) ...
Elimination of autoreactive developing B cells is an important mechanism to prevent autoantibody production. However, how B cell receptor (BCR) signaling triggers apoptosis of immature B cells remains ...
In this MedPage Today video from the recent San Antonio Breast Cancer Symposium (SABCS), Gaia Griguolo, MD, of the Veneto Institute of Oncology in Padua, Italy, presents findings from a study ...
Credit: AstraZeneca. The approval was based on data from the phase 3 CAPItello-291 trial, which included patients with HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN ...
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Imagine that two women have breast cancer with the same subtype: hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). They’re the same age, weight, and height ...
The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback